Fazeli Badrieh, Botzenhardt Sara, Bachhuber Franziska, Klassen Paula, Klose Veronika, Dorst Johannes, Wiesenfarth Maximilian, Uzelac Zeljko, Jesse Sarah, Brenner David, Anderl-Straub Sarah, Ludolph Albert C, Otto Markus, Weishaupt Jochen, Tumani Hayrettin, Halbgebauer Steffen
Department of Neurology, Ulm University Hospital, 89081, Ulm, Germany.
Department of Neurology, Ulm University Hospital, 89081, Ulm, Germany; German Centre for Neurodegenerative Diseases (DZNE e.V.), 89081, Ulm, Germany.
EBioMedicine. 2025 Sep 19;120:105930. doi: 10.1016/j.ebiom.2025.105930.
Neurofilaments are key axonal proteins, with neurofilament light (NfL) and heavy (NfH) chain recognised as promising biomarkers for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). However, neurofilament medium chain (NfM) remained previously underexplored due to a lack of quantitative assays. In this study, we developed a sensitive immunoassay to measure NfM in cerebrospinal fluid (CSF) and analysed its levels in ALS, Alzheimer's disease (AD), frontotemporal dementia (FTD), and Lewy body dementia (LBD). Correlations among neurofilaments and their diagnostic performance were also evaluated.
In this study CSF levels of three neurofilament proteins were measured in 305 participants, including patients with ALS (n = 91), AD (n = 59), FTD (n = 38), LBD (n = 18), non-neurodegenerative controls (CTRL, n = 51), and 48 individuals initially evaluated for ALS but ultimately diagnosed with other conditions (CTRL.DD). NfM levels were quantified using a homemade sandwich ELISA, while NfL and NfH were measured using commercialised Ella cartridges.
All three neurofilaments were significantly elevated in ALS compared to CTRL and CTRL.DD groups (p < 0.0001 for both), with NfM and NfL also increased in FTD (p < 0.0001 for both) and AD (NfM, p < 0.0001; NfL, p = 0.0001) compared to CTRL. NfH demonstrated the greatest distinction between ALS and FTD (p < 0.0001). Strong correlations were observed among neurofilament subunits, particularly between NfM and NfL (r = 0.93, 95% CI: 0.91-0.94, p < 0.0001). All neurofilaments effectively distinguished ALS from CTRL and CTRL.DD, with AUC values ranging from 0.92 to 0.99. NfM and NfL showed high accuracy in differentiating AD (NfM, AUC: 0.91; NfL, AUC: 0.89) and FTD (NfM, AUC: 0.91; NfL, AUC: 0.92) from CTRL, while NfH best separated ALS from FTD (AUC: 0.96).
This study provides a quantitative comparison of NfM with NfL and NfH in a neurodegenerative cohort, highlighting its potential diagnostic value. Further research with larger cohorts, longitudinal studies, and investigations into neurofilament distribution in different compartments is needed to clarify the distinct roles of NfM, NfL, and NfH in the diagnosis and treatment of neurological diseases.
The present study was supported by the Else Kroener-Fresenius Foundation (2024-EKEA.126) and Chemische Fabrik Karl Bucher GmbH.
神经丝是关键的轴突蛋白,神经丝轻链(NfL)和重链(NfH)被认为是肌萎缩侧索硬化症(ALS)等神经退行性疾病有前景的生物标志物。然而,由于缺乏定量检测方法,神经丝中链(NfM)此前研究较少。在本研究中,我们开发了一种灵敏的免疫测定法来检测脑脊液(CSF)中的NfM,并分析其在ALS、阿尔茨海默病(AD)、额颞叶痴呆(FTD)和路易体痴呆(LBD)中的水平。还评估了神经丝之间的相关性及其诊断性能。
在本研究中,检测了305名参与者脑脊液中三种神经丝蛋白的水平,包括ALS患者(n = 91)、AD患者(n = 59)、FTD患者(n = 38)、LBD患者(n = 18)、非神经退行性疾病对照组(CTRL,n = 51),以及48名最初评估为ALS但最终诊断为其他疾病的个体(CTRL.DD)。使用自制的夹心酶联免疫吸附测定法(ELISA)对NfM水平进行定量,而使用商业化的Ella试剂盒检测NfL和NfH。
与CTRL组和CTRL.DD组相比,ALS组中所有三种神经丝均显著升高(两者p < 0.0001),与CTRL组相比,FTD组(两者p < 0.0001)和AD组(NfM,p < 0.0001;NfL,p = 0.0001)中的NfM和NfL也升高。NfH在ALS和FTD之间表现出最大差异(p < 0.0001)。在神经丝亚基之间观察到强相关性,特别是NfM和NfL之间(r = 0.93,95%CI:0.91 - 0.94,p < 0.0001)。所有神经丝都能有效区分ALS与CTRL组和CTRL.DD组,曲线下面积(AUC)值范围为0.92至0.99。NfM和NfL在区分AD(NfM,AUC:0.91;NfL,AUC:0.89)和FTD(NfM,AUC:0.91;NfL,AUC:0.92)与CTRL组时显示出高准确性,而NfH在区分ALS与FTD方面表现最佳(AUC:0.96)。
本研究对神经退行性疾病队列中的NfM与NfL和NfH进行了定量比较,突出了其潜在的诊断价值。需要进一步开展更大队列研究、纵向研究以及对不同脑区神经丝分布的研究,以阐明NfM、NfL和NfH在神经疾病诊断和治疗中的不同作用。
本研究由Else Kroener - Fresenius基金会(2024 - EKEA.126)和Chemische Fabrik Karl Bucher GmbH资助。